- Home
- TKNO vs OCGN Comparison
TKNO vs OCGN Comparison
Compare TKNO & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- OCGN
- Stock Information
- Founded
- TKNO 1996
- OCGN 2013
- Country
- TKNO United States
- OCGN United States
- Employees
- TKNO N/A
- OCGN N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TKNO Health Care
- OCGN Health Care
- Exchange
- TKNO Nasdaq
- OCGN Nasdaq
- Market Cap
- TKNO 256.9M
- OCGN 283.3M
- IPO Year
- TKNO 2021
- OCGN N/A
- Fundamental
- Price
- TKNO $4.35
- OCGN $1.02
- Analyst Decision
- TKNO
- OCGN Strong Buy
- Analyst Count
- TKNO 0
- OCGN 3
- Target Price
- TKNO N/A
- OCGN $6.00
- AVG Volume (30 Days)
- TKNO 221.4K
- OCGN 2.0M
- Earning Date
- TKNO 08-07-2025
- OCGN 08-01-2025
- Dividend Yield
- TKNO N/A
- OCGN N/A
- EPS Growth
- TKNO N/A
- OCGN N/A
- EPS
- TKNO N/A
- OCGN N/A
- Revenue
- TKNO $38,923,000.00
- OCGN $4,754,000.00
- Revenue This Year
- TKNO $9.52
- OCGN N/A
- Revenue Next Year
- TKNO $15.20
- OCGN N/A
- P/E Ratio
- TKNO N/A
- OCGN N/A
- Revenue Growth
- TKNO 11.40
- OCGN N/A
- 52 Week Low
- TKNO $4.00
- OCGN $0.52
- 52 Week High
- TKNO $10.37
- OCGN $1.33
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- OCGN 48.99
- Support Level
- TKNO $4.22
- OCGN $0.98
- Resistance Level
- TKNO $4.94
- OCGN $1.07
- Average True Range (ATR)
- TKNO 0.29
- OCGN 0.04
- MACD
- TKNO -0.00
- OCGN 0.00
- Stochastic Oscillator
- TKNO 16.75
- OCGN 45.65
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").